Grace Therapeutics (GRCE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.89, -3.08% vs the prior close of $1.95.
- Volume 168.65K shares, 1.3x its 50-day average.
- New SEC filings: 4 (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
GRCE slides 3.1% to $1.89. Closed at $1.89, -3.08% vs the prior close of $1.95. Day range $1.85–$2.03, opened at $1.87.
GRCE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GRCE slides 3.1% to $1.89
- Closed at $1.89, -3.08% vs the prior close of $1.95. Day range $1.85–$2.03, opened at $1.87.
- Volume was 168.65K shares, 1.3x its 50-day average of 130.29K.
- Price is -10.7% vs its 50-day average ($2.12) and -34.9% vs its 200-day average ($2.90).
- 52-week range $1.79–$5.18; today's close sits at 3% of that range, 63.5% below the 52-week high.
Oct 15, 2026 — GRCE jumps 3.2% to $1.95
- Closed at $1.95, +3.17% vs the prior close of $1.89. Day range $1.89–$1.97, opened at $1.91.
- Volume was 109.30K shares, 0.8x its 50-day average of 141.09K.
- Price is -8.0% vs its 50-day average ($2.12) and -33.0% vs its 200-day average ($2.91).
- 52-week range $1.79–$5.18; today's close sits at 5% of that range, 62.4% below the 52-week high.
Oct 14, 2026 — GRCE slides 5.0% to $1.89, a 52-week low, 3 down days in a row
- Closed at $1.89, -5.03% vs the prior close of $1.99. Day range $1.85–$2.01, opened at $1.97.
- Volume was 177.90K shares, 1.3x its 50-day average of 139.54K.
- Price is -11.0% vs its 50-day average ($2.12) and -35.2% vs its 200-day average ($2.92).
- 52-week range $1.79–$5.18; today's close sits at 3% of that range, 63.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — GRCE dips 1.5% to $1.99, a 52-week low
- Closed at $1.99, -1.49% vs the prior close of $2.02. Day range $1.97–$2.02, opened at $2.00.
- Volume was 52.40K shares, 0.4x its 50-day average of 140.41K — lighter than usual.
- Price is -6.6% vs its 50-day average ($2.13) and -32.0% vs its 200-day average ($2.93).
- 52-week range $1.79–$5.18; today's close sits at 6% of that range, 61.6% below the 52-week high.
Oct 12, 2026 — GRCE dips 2.9% to $2.02, a 52-week low
- Closed at $2.02, -2.88% vs the prior close of $2.08. Day range $1.98–$2.06, opened at $2.02.
- Volume was 49.60K shares, 0.3x its 50-day average of 142.97K — lighter than usual.
- Price is -5.3% vs its 50-day average ($2.13) and -31.1% vs its 200-day average ($2.93).
- 52-week range $1.79–$5.18; today's close sits at 7% of that range, 61.0% below the 52-week high.
Oct 9, 2026 — GRCE rises 2.0% to $2.08
- Closed at $2.08, +1.96% vs the prior close of $2.04. Day range $2.03–$2.09, opened at $2.05.
- Volume was 37.80K shares, 0.3x its 50-day average of 148.15K — lighter than usual.
- Price is -2.5% vs its 50-day average ($2.13) and -29.2% vs its 200-day average ($2.94).
- 52-week range $1.79–$5.18; today's close sits at 9% of that range, 59.8% below the 52-week high.
Oct 8, 2026 — GRCE dips 2.9% to $2.04
- Closed at $2.04, -2.86% vs the prior close of $2.10. Day range $2.00–$2.07, opened at $2.05.
- Volume was 52.60K shares, 0.3x its 50-day average of 174.23K — lighter than usual.
- Price is -4.4% vs its 50-day average ($2.13) and -30.8% vs its 200-day average ($2.95).
- 52-week range $1.79–$5.18; today's close sits at 7% of that range, 60.6% below the 52-week high.
Oct 7, 2026 — GRCE rises 1.4% to $2.10
- Closed at $2.10, +1.45% vs the prior close of $2.07. Day range $2.05–$2.12, opened at $2.06.
- Volume was 84.30K shares, 0.5x its 50-day average of 182.91K — lighter than usual.
- Price is -1.6% vs its 50-day average ($2.13) and -28.9% vs its 200-day average ($2.95).
- 52-week range $1.79–$5.18; today's close sits at 9% of that range, 59.5% below the 52-week high.
Oct 6, 2026 — GRCE rises 0.5% to $2.07
- Closed at $2.07, +0.49% vs the prior close of $2.06. Day range $2.05–$2.14, opened at $2.08.
- Volume was 110.30K shares, 0.6x its 50-day average of 183.02K.
- Price is -3.1% vs its 50-day average ($2.14) and -30.1% vs its 200-day average ($2.96).
- 52-week range $1.79–$5.18; today's close sits at 8% of that range, 60.0% below the 52-week high.
Oct 5, 2026 — GRCE dips 0.5% to $2.06
- Closed at $2.06, -0.48% vs the prior close of $2.07. Day range $2.01–$2.08, opened at $2.04.
- Volume was 79.00K shares, 0.4x its 50-day average of 183.98K — lighter than usual.
- Price is -3.8% vs its 50-day average ($2.14) and -30.5% vs its 200-day average ($2.97).
- 52-week range $1.79–$5.18; today's close sits at 8% of that range, 60.2% below the 52-week high.
Oct 2, 2026 — GRCE rises 1.5% to $2.07
- Closed at $2.07, +1.47% vs the prior close of $2.04. Day range $2.00–$2.07, opened at $2.04.
- Volume was 105.00K shares, 0.6x its 50-day average of 183.92K — lighter than usual.
- Price is -3.6% vs its 50-day average ($2.15) and -30.4% vs its 200-day average ($2.97).
- 52-week range $1.79–$5.18; today's close sits at 8% of that range, 60.0% below the 52-week high.
GRCE latest news & SEC filings
Every SEC filing by or about GRCE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Opaleye Management Inc. bought 11,233 shares at $1.93 (≈$21.73K) on Oct 14, 2026; now holds 2,884,522
- Opaleye Management Inc. bought 23,485 shares at $1.95 (≈$45.69K) on Oct 15, 2026; now holds 2,908,007
- Opaleye Management Inc. bought 36,347 shares at $1.89 (≈$68.76K) on Oct 16, 2026; now holds 2,944,354
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Opaleye Management Inc. bought 2,077 shares at $2.02 (≈$4.19K) on Oct 8, 2026; now holds 2,860,734
- Opaleye Management Inc. bought 5,340 shares at $2.04 (≈$10.92K) on Oct 9, 2026; now holds 2,866,074
- Opaleye Management Inc. bought 7,215 shares at $2.02 (≈$14.57K) on Oct 12, 2026; now holds 2,873,289
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Opaleye Management Inc. bought 38,796 shares at $2.04 (≈$78.96K) on Oct 1, 2026; now holds 2,836,963
- Opaleye Management Inc. bought 20,000 shares at $2.07 (≈$41.37K) on Oct 2, 2026; now holds 2,856,963
- Opaleye Management Inc. bought 1,694 shares at $2.06 (≈$3.49K) on Oct 5, 2026; now holds 2,858,657
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Opaleye Management Inc. bought 7,849 shares at $2.09 (≈$16.40K) on Sep 29, 2026; now holds 2,798,167
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
- Opaleye Management Inc. bought 9,771 shares at $2.10 (≈$20.52K) on Sep 21, 2026; now holds 2,785,000
- Opaleye Management Inc. bought 5,318 shares at $2.10 (≈$11.17K) on Sep 23, 2026; now holds 2,790,318
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Opaleye Management Inc. bought 9,771 shares at $2.10 (≈$20.52K) on Sep 21, 2026; now holds 2,850,000
- Opaleye Management Inc. bought 5,318 shares at $2.10 (≈$11.17K) on Sep 23, 2026; now holds 2,855,318
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Aug 31, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 24, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$15.79M (prior year -$3.36M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.91 (prior year -$0.21) (loss widened vs Jun 30, 2025)
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade GRCE
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: Jun 18, 2026, Feb 12, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.94% (largest 5.1%).
- Liquidity: about 106.82K shares (≈$201.89K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.89 vs a range of $1.79–$5.18 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 24 open-market buys, 0 sales; latest: Management Inc. Opaleye bought 5,318 shares on Sep 23, 2026.
- Latest filings: 8-K Sep 18, 2026; 8-K Aug 13, 2026; 10-Q Aug 13, 2026.
- Share count: 21.04M shares outstanding (Aug 11, 2026), +52.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GRCE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.87 | 2.03 | 1.85 | 1.89 | 168.65K |
| Oct 15, 2026 | 1.91 | 1.97 | 1.89 | 1.95 | 109.30K |
| Oct 14, 2026 | 1.97 | 2.01 | 1.85 | 1.89 | 177.90K |
| Oct 13, 2026 | 2.00 | 2.02 | 1.97 | 1.99 | 52.40K |
| Oct 12, 2026 | 2.02 | 2.06 | 1.98 | 2.02 | 49.60K |
| Oct 9, 2026 | 2.05 | 2.09 | 2.03 | 2.08 | 37.80K |
| Oct 8, 2026 | 2.05 | 2.07 | 2.00 | 2.04 | 52.60K |
| Oct 7, 2026 | 2.06 | 2.12 | 2.05 | 2.10 | 84.30K |
| Oct 6, 2026 | 2.08 | 2.14 | 2.05 | 2.07 | 110.30K |
| Oct 5, 2026 | 2.04 | 2.08 | 2.01 | 2.06 | 79.00K |
| Oct 2, 2026 | 2.04 | 2.07 | 2.00 | 2.07 | 105.00K |
| Oct 1, 2026 | 2.11 | 2.13 | 1.98 | 2.04 | 344.20K |
| Sep 30, 2026 | 2.14 | 2.16 | 2.10 | 2.15 | 25.30K |
| Sep 29, 2026 | 2.11 | 2.15 | 2.09 | 2.11 | 130.20K |
| Sep 28, 2026 | 2.12 | 2.14 | 2.09 | 2.12 | 58.70K |
| Sep 25, 2026 | 2.14 | 2.14 | 2.10 | 2.12 | 80.20K |
| Sep 24, 2026 | 2.17 | 2.18 | 2.09 | 2.16 | 106.30K |
| Sep 23, 2026 | 2.15 | 2.15 | 2.09 | 2.12 | 184.70K |
| Sep 22, 2026 | 2.09 | 2.17 | 2.08 | 2.14 | 70.10K |
| Sep 21, 2026 | 2.12 | 2.15 | 2.08 | 2.10 | 109.90K |
About Grace Therapeutics
Grace Therapeutics (GRCE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends March 31. SEC CIK 1444192.
GRCE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| A Brian Davis | Director | Sep 21, 2026 |
| Vimal Kavuru | Director | Sep 21, 2026 |
| Prashant Kohli | Chief Executive Officer | Sep 10, 2026 |
| George Kottayil | Director | Sep 21, 2026 |
| Edward Neugeboren | Director | Sep 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert J Delaversano | Principal Financial Officer | Sep 1, 2026 |
| Prashant Kohli | Chief Executive Officer | Sep 10, 2026 |
| Amresh Kumar | VP Program Management | Sep 1, 2026 |
| R. Loch Macdonald | Chief Medical Officer | Sep 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 23, 2026 | Management Inc. Opaleye | Buy | 5,318 | $2.10 |
| Sep 23, 2026 | Management Inc. Opaleye | Buy | 5,318 | $2.10 |
| Sep 23, 2026 | Management Inc. Opaleye | Buy | 5,318 | $2.10 |
| Sep 23, 2026 | Management Inc. Opaleye | Buy | 5,318 | $2.10 |
| Sep 21, 2026 | Management Inc. Opaleye | Buy | 9,771 | $2.10 |
| Sep 21, 2026 | Management Inc. Opaleye | Buy | 9,771 | $2.10 |
| Sep 21, 2026 | Management Inc. Opaleye | Buy | 9,771 | $2.10 |
| Sep 21, 2026 | Management Inc. Opaleye | Buy | 9,771 | $2.10 |
| Sep 9, 2026 | Management Inc. Opaleye | Buy | 5,836 | $2.09 |
| Sep 9, 2026 | Management Inc. Opaleye | Buy | 5,836 | $2.09 |
| Sep 9, 2026 | Management Inc. Opaleye | Buy | 5,836 | $2.09 |
| Sep 9, 2026 | Management Inc. Opaleye | Buy | 5,836 | $2.09 |
| Sep 9, 2026 | Prashant Kohli | Buy | 100,000 | $2.14 |
| Sep 9, 2026 | Prashant Kohli | Buy | 100,000 | $2.14 |
| Sep 9, 2026 | Prashant Kohli | Buy | 100,000 | $2.14 |
GRCE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Mar 31, 2026 | — | $-7.79M | -0.47 | $-8.87M |
| Mar 31, 2025 | — | $-9.57M | -0.79 | $-14.90M |
| Mar 31, 2024 | — | $-12.85M | -1.35 | $-12.33M |
| Mar 31, 2023 | — | $-42.43M | -5.71 | $-15.91M |
| Mar 31, 2022 | $100.00M | $-9.82M | -0.27 | $-17.23M |
Latest balance sheet: total assets $50.07M, total liabilities $1.86M, cash $13.76M (as of Jun 30, 2026).
GRCE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $2.07 |
| Jun 18, 2026 | 8-K Item 2.02 (results) | $2.38 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $3.53 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $3.10 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $3.21 |
| Jun 23, 2025 | 8-K Item 2.02 (results) | $2.93 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $3.48 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $3.05 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| Jun 21, 2024 | 8-K Item 2.02 (results) | — |
| Feb 12, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GRCE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.